$468 $279 for your first year. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Offer available here until 24th October.

UCB taps new UK head. Belgium-based global biopharmaceutical company UCB welcomed Nico Reynders as its new general manager ...

Why a Malvern biopharma is exploring combining its lead drug candidate targeting Alzheimer's and Parkinson's diseases with a ...

ELI LILLY Inc. LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and ...

Dana Filmore, a grandmother from Columbus, Ohio, is among thousands of plaintiffs filing a federal lawsuit against pharmaceutical companies Novo Nordisk and Eli Lilly, alleging Ozempic and Mounjaro ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.

Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly ...

Here, Hancock cites fund holding Eli Lilly and its patents on GLP-1 weight loss drugs Mounjaro and Zepbound. Hancock expects ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...